Valence 로고
인기
로그인

관심목록에 추가

Perspective Therapeutics ...

NYSE American: CATX · 실시간 가격 · USD
3.21
-0.01 (-0.31%)
종가 기준: Aug 18, 2026, 3:59 PM
3.25
+1.25%
애프터마켓: 7:30 PM

Perspective Therapeutics Inc. (CATX) Stock Price, Analysis & Data

-0.31%
매수호가3.25
시가총액366.43M
매출 (ttm)409K
순이익 (ttm)-116.63M
베타1.80
EPS (ttm)-1.33
P/E (ttm)n/a
선행 P/E-2.91
P/B (ttm)1.13
P/S (ttm)895.91
Earnings DateNov 9, 2026
매도호가3.5
거래량757,296
평균 거래량 (20일)1,682,932
시가3.21
전일 종가3.22
일중 범위3.12 - 3.25
52주 범위1.96 - 6.16
애널리스트Strong Buy
목표주가13 (304.98%)
배당n/a
배당락일n/a

CATX 소개

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted r...

[더 보기]
산업 Medical Devices
섹터 Healthcare
IPO 일자 Nov 10, 2005
직원 수 163
상장 거래소 NYSE American
티커 CATX
웹사이트 https://www.perspectivetherapeutics.com
전체 기업 정보

재무 실적

2025년 Perspective Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -103.12M로, 30.07% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 14명의 투자의견을 종합하면 CATX 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 13로, 최근 주가 대비 304.98% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Perspective Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.22 예상치 상회 0.05, 및 26.67% 전년 대비 성장.

    • 다음 실적 발표

    Perspective Therapeutics Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · MT Newswires

    Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says

    Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

    news image

    1주 전 · Zacks

    Profound Medical (PROF) Q2 Earnings Surpass Estimates

    Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2주 전 · Zacks

    Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

    Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

    news image

    2주 전 · Zacks

    4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

    Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

    news image

    2주 전 · Zacks

    Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

    After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings...

    2 페이지 중 1